Diseases Research Consortium (IRDiRC), as their newest member, to further advance their common goal to change the pace at which new therapies for rare diseases can be discovered and brought to patients. Millions of people worldwide are affected by rare diseases and 95 percent of those diseases do not have an approved therapy.
Recursion combines the best elements of automated biology and artificial intelligence to create a highly scalable drug discovery platform that is capable of finding new drugs and new ways to use old drugs, while simultaneously working on many diseases in parallel. The company has focused specifically on rare genetic disease treatments, and have identified two new therapies that will likely move to Investigational New Drug (IND) status this year, with more than a dozen additional therapies in the pipeline. The boldly stated corporate goal is 100 treatments by 2025.
“It is a natural fit for Recursion to be aligned with IRDiRC as we both have a passion for improving the lives of people with rare diseases,” said Chris Gibson, CEO of Recursion Pharmaceuticals. “We are confident the work we are doing can propel the discovery process for rare disease treatments, and we hope through our work and the work of our partners at IRDiRC, we can fundamentally shift the curve to get more therapies to more patients sooner.”
IRDiRC teams up researchers and organizations investing in rare diseases research to collaborate, pool expertise, and leverage resources in order to be efficient and streamline processes. IRDiRC is focused on improving the efficiency and effectiveness of rare diseases research, diagnosis, and treatment to accelerate medical breakthroughs for people affected by rare diseases.
In a statement from IRDiRC: “We warmly welcome Recursion Pharmaceuticals as a new member. We fully support them in fulfilling their challenging goal to discover 100 treatments for rare diseases by the year 2025. This goal is perfectly aligned with IRDiRC’s objectives for therapeutic development and will help us progress to the ultimate goal of benefitting rare disease patients worldwide.”
Recursion Pharmaceuticals is an emerging biotechnology company based in Salt Lake City. Recursion combines experimental biology and bioinformatics with artificial intelligence in a massively parallel system to quickly and efficiently identify treatments for any disease which can be modeled at the cellular level. From its initial and continued focus on drug repurposing to treat rare diseases, Recursion has broadened its platform to probe rich data from high-throughput automated screens for a number of indications, including aging, inflammation, infectious disease, oncology, and diagnostics. Recursion’s ultimate vision is to leverage technology to build a robust and reliable map of human cellular biology, which would enable a radical shift in the pace and scale at which new treatments could benefit patients. Learn more at www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.